Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Summary

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

Timeline

Start

2018-08-27

Primary completion

2027-12-31

Completion

2029-12-31

Drugs

Indications